lobbying_filings_raw: e09bcadb-8d8e-4e02-a06a-815b2f44dd7b
This data as json
| filing_uuid | filing_type | registrant_id | registrant_name | client_id | client_name | filing_year | filing_period | received_date | amount_reported | is_amendment | is_no_activity | is_termination | raw_json |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| e09bcadb-8d8e-4e02-a06a-815b2f44dd7b | Q2 | 1923 | AMERICAN CLINICAL LABORATORY ASSN | 102665 | AMERICAN CLINICAL LABORATORY ASSN | 2023 | second_quarter | 2023-07-18T11:26:24-04:00 | 633739.0 | 0 | 0 | 0 | {"url": "https://lda.senate.gov/api/v1/filings/e09bcadb-8d8e-4e02-a06a-815b2f44dd7b/", "filing_uuid": "e09bcadb-8d8e-4e02-a06a-815b2f44dd7b", "filing_type": "Q2", "filing_type_display": "2nd Quarter - Report", "filing_year": 2023, "filing_period": "second_quarter", "filing_period_display": "2nd Quarter (Apr 1 - June 30)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/e09bcadb-8d8e-4e02-a06a-815b2f44dd7b/print/", "filing_document_content_type": "text/html", "income": null, "expenses": "633739.00", "expenses_method": "C", "expenses_method_display": "C", "posted_by_name": "Holly Grosholz", "dt_posted": "2023-07-18T11:26:24-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "1201 Pennsylvania Ave, NW", "registrant_address_2": "Suite 810", "registrant_different_address": true, "registrant_city": "WASHINGTON", "registrant_state": "DC", "registrant_zip": "20004", "registrant": {"id": 1923, "url": "https://lda.senate.gov/api/v1/registrants/1923/", "house_registrant_id": 30533, "name": "AMERICAN CLINICAL LABORATORY ASSN", "description": "national trade association for clinical laboratories", "address_1": "1201 Pennsylvania Ave, NW", "address_2": "Suite 810", "address_3": null, "address_4": null, "city": "WASHINGTON", "state": "DC", "state_display": "District of Columbia", "zip": "20004", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "HOLLY BRUGGEN", "contact_telephone": "+1 202-637-9466", "dt_updated": "2026-01-20T16:03:44.906224-05:00"}, "client": {"id": 102665, "url": "https://lda.senate.gov/api/v1/clients/102665/", "client_id": 12, "name": "AMERICAN CLINICAL LABORATORY ASSN", "general_description": null, "client_government_entity": false, "client_self_select": true, "state": "DC", "state_display": "District of Columbia", "country": "US", "country_display": "United States of America", "ppb_state": "DC", "ppb_state_display": "District of Columbia", "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2012-12-07"}, "lobbying_activities": [{"general_issue_code": "MED", "general_issue_code_display": "Medical/Disease Research/Clinical Labs", "description": "Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417); price transparency for clinical laboratory services, FY 2024 budget and appropriations processes Saving Access to Laboratory Services Act H.R. 2377/S. 1000, VALID Act H.R. 2369; H.R. 3791, Improving Data in Public Health Act; H.R. 3248, Diagnostic Lab Testing Transparency Act;", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 139358, "prefix": null, "prefix_display": null, "first_name": "SUSAN", "nickname": null, "middle_name": null, "last_name": "VAN METER", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 141271, "prefix": null, "prefix_display": null, "first_name": "HOLLY", "nickname": null, "middle_name": null, "last_name": "GROSHOLZ", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 134, "name": "Centers For Disease Control & Prevention (CDC)"}, {"id": 136, "name": "Centers For Medicare and Medicaid Services (CMS)"}, {"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}, {"id": 12, "name": "White House Office"}]}, {"general_issue_code": "MMM", "general_issue_code_display": "Medicare/Medicaid", "description": "Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); access to clinical laboratory services pursuant to a telehealth visit Saving Access to Laboratory Services Act H.R. 2377/S. 1000,", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 139358, "prefix": null, "prefix_display": null, "first_name": "SUSAN", "nickname": null, "middle_name": null, "last_name": "VAN METER", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 141271, "prefix": null, "prefix_display": null, "first_name": "HOLLY", "nickname": null, "middle_name": null, "last_name": "GROSHOLZ", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 136, "name": "Centers For Medicare and Medicaid Services (CMS)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}, {"id": 12, "name": "White House Office"}]}, {"general_issue_code": "BUD", "general_issue_code_display": "Budget/Appropriations", "description": "Policies related to diagnostics and laboratory regulation", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 139358, "prefix": null, "prefix_display": null, "first_name": "SUSAN", "nickname": null, "middle_name": null, "last_name": "VAN METER", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 141271, "prefix": null, "prefix_display": null, "first_name": "HOLLY", "nickname": null, "middle_name": null, "last_name": "GROSHOLZ", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "HCR", "general_issue_code_display": "Health Issues", "description": "Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417); price transparency for clinical laboratory services, FY 2024 budget and appropriations processes Saving Access to Laboratory Services Act H.R. 2377/S. 1000, VALID Act H.R. 2369; H.R. 3791, Improving Data in Public Health Act; H.R. 3248, Diagnostic Lab Testing Transparency Act;", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 139358, "prefix": null, "prefix_display": null, "first_name": "SUSAN", "nickname": null, "middle_name": null, "last_name": "VAN METER", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 141271, "prefix": null, "prefix_display": null, "first_name": "HOLLY", "nickname": null, "middle_name": null, "last_name": "GROSHOLZ", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 134, "name": "Centers For Disease Control & Prevention (CDC)"}, {"id": 136, "name": "Centers For Medicare and Medicaid Services (CMS)"}, {"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}, {"id": 12, "name": "White House Office"}]}, {"general_issue_code": "DIS", "general_issue_code_display": "Disaster Planning/Emergencies", "description": "Reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417) Improving Data in Public Health Act (H.R. 3791)", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 139358, "prefix": null, "prefix_display": null, "first_name": "SUSAN", "nickname": null, "middle_name": null, "last_name": "VAN METER", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 141271, "prefix": null, "prefix_display": null, "first_name": "HOLLY", "nickname": null, "middle_name": null, "last_name": "GROSHOLZ", "suffix": null, "suffix_display": null}, "covered_position": null, "new": true}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} |